Protagenic Therapeutics (NASDAQ:PTIX) Posts Quarterly Earnings Results

Protagenic Therapeutics (NASDAQ:PTIX) posted its quarterly earnings data on Monday. The company reported ($0.24) EPS for the quarter, Zacks reports.

Protagenic Therapeutics Trading Down 13.3 %

PTIX traded down $0.03 during midday trading on Monday, reaching $0.20. The company’s stock had a trading volume of 130,863 shares, compared to its average volume of 636,276. Protagenic Therapeutics has a twelve month low of $0.19 and a twelve month high of $1.87. The stock has a market cap of $1.41 million, a P/E ratio of -0.15 and a beta of 0.43. The company has a fifty day simple moving average of $0.31 and a 200 day simple moving average of $0.49.

Protagenic Therapeutics Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.